ATH 0.00% 0.4¢ alterity therapeutics limited

end of the downside- back in, page-55

  1. 516 Posts.
    lightbulb Created with Sketch. 13
    It is not true. The failure of Imagine was a disaster, but at that time, the company had ample cash reserve and three leading candidates in the pipeline. It was still a promising one if the management team did something right. Then the CEO and his partners wasted all their resources and thirty months negotiating with FDA. Currently the share price is only about one tenth of the opening price after Imagine failure.

    Their communication and ambiguous language are always troublesome to investors, e.g., this time they delivered very encouraging information about the meeting with FDA, but they never inform you when the P2 trial can actually start. They may imply that they will do a one-year natural history study first. The P2 trial may only start after they collect all the data and work together with FDA to figure out feasible efficacy endpoints. How long time do they need??? Can they survive until the day we see the kickoff? I believe MMs do like this company. They can easily double the share price when people are expecting something good. After that, the share price was always relentlessly drawn down to new historical lows. It was repeated again and again.

    I have cleared all my holdings. This time I wouldn't stay here as a desperate LT shareholder. I don't mind to buy back some shares at higher cost in the future if there is a clear entry signal. The room is huge if they really succeed in something.
    Last edited by sgsundy: 11/07/20
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $18.62M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $4.887K 1.626M

Buyers (Bids)

No. Vol. Price($)
48 57027004 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 125241201 25
View Market Depth
Last trade - 10.38am 02/09/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.